0001493152-18-015254.txt : 20181106 0001493152-18-015254.hdr.sgml : 20181106 20181106151226 ACCESSION NUMBER: 0001493152-18-015254 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20181101 ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20181106 DATE AS OF CHANGE: 20181106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PROLUNG INC CENTRAL INDEX KEY: 0001541884 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 201922768 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38362 FILM NUMBER: 181162708 BUSINESS ADDRESS: STREET 1: 757 EAST SOUTH TEMPLE, SUITE 150 CITY: SALT LAKE CITY STATE: UT ZIP: 84102 BUSINESS PHONE: 801-204-9623 MAIL ADDRESS: STREET 1: 757 EAST SOUTH TEMPLE, SUITE 150 CITY: SALT LAKE CITY STATE: UT ZIP: 84102 FORMER COMPANY: FORMER CONFORMED NAME: FRESH MEDICAL LABORATORIES, INC. DATE OF NAME CHANGE: 20120209 8-K 1 form8-k.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (date of earliest event reported): November 1, 2018

 

ProLung, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware   001-38362   20-1922768
(State or other jurisdiction of   (Commission   (IRS Employer
incorporation or organization)   File Number)   Identification No.)

 

757 East South Temple, Suite 150    
Salt Lake City, Utah   84102
(Address of Principal Executive Offices)   (Zip Code)

 

(801) 736-0729

(Registrant’s Telephone Number, Including Area Code)

 

N/A

(Former name, former address, and formal fiscal year, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  [  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
  [  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
  [  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)
     
  [  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)
     
  [  ] Emerging growth Company
     
  [  ] If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 12(a) of the Exchange Act

 

 

 

   
 

 

Item 5.03. Amendments to Articles of Incorporation or Bylaws.

 

On November 1, 2018, the board of directors (the “Board”) of ProLung, Inc. (the “Company”), following a deliberative review of the Company’s quorum requirements, adopted Amendment No. 1 (the “Amendment”) to the First Amended and Restated Bylaws of the Company (the “Bylaws”). The Amendment was effective immediately and provides that a quorum exists when the holders of shares of common stock of the Company (the “Common Stock”) having at least one-third of the votes which could be cast by the holders of all outstanding shares of Common Stock entitled to vote at each meeting of stockholders, are present in person or represented by proxy.

 

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the complete text of the Amendment, which is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

3.1 Amendment No. 1 to the Bylaws of ProLung, Inc., dated November 1, 2018.

 

   
 

 

Signatures

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 6, 2018 ProLung, Inc.
     
  By: /s/ Jared Bauer
  Name: Jared Bauer
  Title: Interim Chief Executive Officer

 

   
 

 

EXHIBIT INDEX

 

3.1 Amendment No. 1 to the Bylaws of ProLung, Inc., dated November 1, 2018.

 

   
 

EX-3.1 2 ex3-1.htm

 

AMENDMENT NO. 1 TO

 

BYLAWS OF

 

PROLUNG, INC.

 

This Amendment No. 1 to the First Amended and Restated Bylaws (the “Bylaws”) of ProLung, Inc., a Delaware corporation (the “Company”), is dated as of November 1, 2018 (this “Amendment No. 1”).

 

Recitals

 

WHEREAS, the Board of Directors of the Corporation (the “Board”) has approved Amendment No. 1 as set forth below, in accordance with Article 8, Section 6 of the Bylaws.

 

NOW, THEREFORE, BE IT RESOLVED, the Bylaws are hereby amended as follows:

 

The first sentence of Article 1, Section 5 is hereby deleted in its entirety and replaced with a new sentence as follows:

 

Except as otherwise provided by law, the certificate of incorporation or these bylaws, at each meeting of stockholders the presence in person or by proxy of the holders of shares of stock having at least one-third of the votes which could be cast by the holders of all outstanding shares of stock entitled to vote at the meeting shall be necessary and sufficient to constitute a quorum.